159 related articles for article (PubMed ID: 35623801)
1. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
2. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
[TBL] [Abstract][Full Text] [Related]
4. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.
Guan J; Yang Q; Chen C; Wang G; Zhu H
EXCLI J; 2021; 20():1-16. PubMed ID: 33510588
[TBL] [Abstract][Full Text] [Related]
7. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
[TBL] [Abstract][Full Text] [Related]
8. Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.
Thormann M; Omari J; Pech M; Damm R; Croner R; Perrakis A; Strobel A; Wienke A; Surov A
Langenbecks Arch Surg; 2022 Jun; 407(4):1369-1379. PubMed ID: 35583832
[TBL] [Abstract][Full Text] [Related]
9. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.
Surov A; Pech M; Gessner D; Mikusko M; Fischer T; Alter M; Wienke A
Clin Nutr; 2021 Oct; 40(10):5298-5310. PubMed ID: 34536638
[TBL] [Abstract][Full Text] [Related]
10. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
Meyer HJ; Wienke A; Zamsheva M; Surov A
Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
[TBL] [Abstract][Full Text] [Related]
11. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
Meyer HJ; Wienke A; Surov A
Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
[TBL] [Abstract][Full Text] [Related]
13. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
[TBL] [Abstract][Full Text] [Related]
14. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
[TBL] [Abstract][Full Text] [Related]
15. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
16. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
17. The impact of
Xu X; Qian Y; Jin K; Chen J; Fu J; Chen C; Zhu Z
Front Cell Infect Microbiol; 2023; 13():1289909. PubMed ID: 38235492
[TBL] [Abstract][Full Text] [Related]
18. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
Surov A; Strobel A; Borggrefe J; Wienke A
Eur Radiol; 2023 Sep; 33(9):6426-6437. PubMed ID: 36929392
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Imaging-Diagnosed Sarcopenia on Long-term Prognosis After Curative Resection for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Kong Q; Gao Q; Li W; Chen Z
Acad Radiol; 2024 Apr; 31(4):1272-1283. PubMed ID: 38071101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
